



# PROMETHEUS LABORATORIES

5739 Pacific Center Blvd.  
San Diego CA 92121  
Toll Free: 888/423-5227  
www.prometheuslabs.com

## Test Results

## SAMPLE REPORT

### PRO-Predict<sup>®</sup> Metabolites<sup>‡</sup>

Azathioprine and 6-MP metabolite monitoring

#### Patient & Order Information

Order ID **419589**  
Patient **Test, Patient**  
DOB **01/10/1900**  
SSN **123-45-6789** Sex **M**  
Institution ID Promethus ID **21740**  
Ordered **03/06/2003** Completed **03/08/2003**  
Ordered By **Example Physician M.D.**  
ICD9 Codes **789.00**

#### Report Recipient

Example Physician M.D.  
Prometheus Laboratories Inc.  
5739 Pacific Center Blvd  
Suite 123  
San Diego, CA 92121  
USA  
858/824-0895 Phone 858/824-0896 Fax



Sample ID: SZ10000008 Collection Date: 03/05/2003 8:15AM (Whole Blood) Institution Sample ID:

#### Test Results

Metabolite	Result (Units: pmole/8 x 10 <sup>8</sup> RBC )	Reference Range	Result Assessment
6-TGN	250	230-400	Higher Likelihood of Response.
6-MMPN	3920	< 5700	Lower Risk of Hepatotoxicity.

#### Cumulative PRO-Predict<sup>®</sup> Metabolites<sup>‡</sup>

#### Patient Results



Collection Date	Sample ID	6-TGN Level	6-MMPN Level	Drug	Dosage
03/05/2003 08:15 AM	SZ10000008	250	3920	Azathioprine	125 mg/day
01/16/2003 11:00 AM	SZ10000007	173	2192	Azathioprine	125 mg/day
11/12/2002 10:52 AM	SZ10000006	262	4720	Azathioprine	125 mg/day
05/28/2002 10:30 AM	SZ10000005	314	5040	Azathioprine	125 mg/day
04/12/2002 09:33 AM	SZ10000004	448	6720	Azathioprine	150 mg/day
03/17/2002 10:41 AM	SZ10000003	189	4880	Azathioprine	100 mg/day
02/21/2002 09:52 AM	SZ10000002	166	2061	Azathioprine	100 mg/day
01/14/2002 11:21 AM	SZ10000001	102	< the lower limit of detection (901)	Azathioprine	75 mg/day
12/03/2001 10:50 AM	SA10000000	116	< the lower limit of detection (301)	Azathioprine	50 mg/day

<sup>‡</sup> Proprietary and patented technology by Prometheus Laboratories Inc. The therapeutic range and toxic thresholds were established in an IBD patient population receiving azathioprine or 6-mercaptopurine. Metabolite testing should not replace laboratory monitoring for toxicity.

Previous PRO-Predict <sup>®</sup> TPMT Patient Test Results.					
Test Name	Collection Date	Report Date	Sample ID	Result	Interpretation
PRO-Predict <sup>®</sup> TPMT	01/12/2002	01/19/2002	SC01050042	TPMT*1/TPMT*1	Normal

#### References

- Dubinsky M, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in patients with inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
- Seidman EG. Recent Advances in the diagnosis and treatment of pediatric inflammatory bowel disease. Gastroenterol Rep. 2000;1:248-252.
- Cuffari C, et al. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-646.
- Seidman, EG. Clinical use and practical application of TPMT Enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3(suppl 1):S30-S38.
- Rumbo C, et al. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: A preliminary report. J Ped Gastro Nutr. 2002;35:391-398.
- Lennard L, et al. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43(4):329-339.
- Lennard L. Clinical implication of thiopurine methyltransferase-Optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998;20(5):527-531.
- Louis E, Belaiche J. Optimizing treatment with thioguanine derivative in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003;17(1):37-46.